Everest Medicines ‘s licensing partner, Venatorx Pharmaceuticals announced that The New England Journal of Medicine published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections, including acute pyelonephritis.
